The spending impact is already visible elsewhere in the food and drink market
Davina is such a welcoming and friendly soul with wealth of knowledge
Hopefully, this will drive policy changes, lower prices, and expand access, while also marking an important shift: seeing obesity as a disease that deserves proactive, evidence-based treatment. While semaglutide is the most prominent of them all, dulaglutide and liraglutide, as well as the dual GLP-1/GIP agonist GIP plays a similar role to GLP-1 tirzepatide, present in Lillys Mounjaro and Zepbound, also join the list as therapeutic alternatives. Even biosimilars, which are drugs that are highly similar to biologics with regard to their quality, safety, and efficacy, were listed
Semaglutide and other GLP-1 medications have turned the tide in the battle against obesity
Meet the experts Dr